×

RNS Number : 0738K

Avanti Communications Group Plc

06 April 2018

 

Avanti Communications Group Plc

Successful launch of HYLAS 4

Avanti Communications Group Plc ("Avanti") a leading satellite operator, providing Ka-band satellite data communications services across the UK, Europe, the Middle East and Africa, announces the successful launch of HYLAS 4 from Kourou, French Guiana on Ariane Flight VA242 on Thursday 5th April 2018.

The Ariane 5 rocket launched HYLAS 4 into the correct orbit on schedule. HYLAS 4 successfully separated from the Ariane 5 on time and telemetry was received by the control centre at the European Spaceport.

David Bestwick, Chief Technology Officer of Avanti Communications, said:
"I'm pleased to announce HYLAS 4 has been successfully launched and is operating under our control. The satellite will undertake a series of pre-planned in orbit acceptance tests over the coming months before we commence service for customers.

"HYLAS 4 will set the new standard of affordability, quality and flexibility to Internet Service Providers, Mobile Network Operators, Governments and other Satellite Operators. The High Throughput Satellite (HTS) has 64 Ka-band spot beams that complement our existing coverage across Europe, East and Southern Africa, as well as providing new capacity across West and Central Africa. Furthermore, HYLAS 4 has 4 steerable beams which can provide highly flexible capacity across Africa and Latin America."

 

For further information, please contact:

Avanti Communications	Nigel Fox, Patrick Willcocks Tel: +44 20 7749 1600
Montfort	Nick Miles,  James Olley Tel: +44 203 770 7909
Cenkos Securities (Nomad)	Max Hartley, Nicholas Wells Tel: +44 207 397 8900
Redleaf Communications	Ralph Anderson +44 (0)20 3757 6883

 

About Avanti

Avanti connects people wherever they are – in their homes, businesses, in government and on mobiles. Through the HYLAS satellite fleet and partners in 118 countries, the network provides ubiquitous internet service to a quarter of the world's population.

Avanti delivers the level of quality and flexibility that the most demanding telecoms customers in the world seek. Avanti is the first mover in high throughput satellite data communications in EMEA. It has rights to orbital slots and KA-band spectrum in perpetuity that covers an end market of over 1.7bn people. The Group has invested $1.2bn in a network that incorporates satellites, ground stations, datacentres and a fibre ring.

Avanti has a unique Cloud-based customer interface that is protected by patented technology. Avanti Communications is listed in London on AIM (AVN: LSE). www.avantiplc.com 

 

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

MSCGUGDSSUGBGIL

Close

×

Neville Registrars is delighted to welcome Artilium plc as the newest addition to its list of client companies.

Artilium plc is a leading Mobile Virtual Network Enabler (MVNE) through its own state of the art Cloud platform.

Further information can be found on the Company's website: https://www.artilium.com/

Close

×

RNS Number : 3171J

Sativa Investments PLC

29 March 2018

 

 

 

Press release

Thursday 29 March 2018

Sativa Investments PLC

 

 ("Sativa" or "the Company")

 

Admission to NEX Exchange Growth Market having raised £1.1 million

 

Sativa Investments PLC, the UK's first medicinal cannabis Investment Vehicle, is pleased to announce that trading in its Ordinary Shares will commence at 8.00 a.m. today on the NEX Exchange Growth Market ("Admission"), under ticker SATI and ISIN number GB00BFX17474. 

 

Sativa will look for well-placed opportunities within the dynamic regulatory environment of the Medicinal Cannabis sector and the Company's investment strategy will focus on the production, testing and compliance, research and development, including pharmacology, commercialisation and sales and marketing of Medicinal Cannabis in jurisdictions where it is regulatorily accepted, with an initial focus on Canada.  The Company has committed to an independent legal review prior to each investment to verify compliance with the prevailing regulatory environment. 

 

Key highlights

 

·     On Admission the Company will have estimated net cash, including the Subscription proceeds, of £1,548,040 

 

·    The Company has raised £1,100,000 pursuant to the Subscription, to invest in and acquire control of certain target companies, although it may also consider acquiring non-controlling shareholdings in targeted Medicinal Cannabis businesses, following advice from the Company's Medical Cannabis Advisory Board. 

 

·     Sativa Investments will seek returns from the dynamic regulatory environment surrounding Medicinal Cannabis and will invest in well-placed businesses involved in production, testing and compliance, research and development, including pharmacology, commercialisation and sales and marketing of Medicinal Cannabis. 

 

·   While there are a large number of active cannabinoids found in Cannabis, Medicinal Cannabis has two cannabinoid components that can potentially treat human pain, disease and symptoms; tetrahydrocannabinol (THC) and cannabidiol (CBD). 

 

·     These two components of Medicinal Cannabis can potentially treat muscle spasticity and nausea, along with treating chronic pain by activating pathways in the central nervous system, which work to block pain signals through cannabinoid receptors.  As outlined by Leafscience, a provider of health and science information to Cannabis consumers and professionals, the product can also reduce the pain and discomfort of diseases such as cancer, glaucoma, liver disease, Parkinson's disease, traumatic brain injury, spinal cord injury and multiple sclerosis.  It is also believed to assist patients with post-traumatic stress disorder (PTSD), and relieves convulsion and inflammation. 

 

·     The Medicinal Cannabis sector is growing rapidly across the globe.  For example, the Medicinal Cannabis market in Ontario, Canada, is projected to climb from CA$379 million in 2018 to CA$2.22 billion by 2021, according to Brightfield Group projections, being an increase of 485 per cent increase in three years.  The demand for Medicinal Cannabis is soaring also in the Netherlands where, over the past five years, the number of doctor's prescriptions for Medicinal Cannabis grew by more than 400 per cent to over 50,000 in 2017, according to figures from the Foundation for Pharmaceutical Statistics (SFK).  The use of Medicinal Cannabis, which is only available with a doctor's prescription, took off in the Netherlands in 2016 with an increase of 75 per cent.  Jan Dirk Kroon of the SFK estimates that around 8,000 people in the Netherlands use Medicinal Cannabis. 

 

Management with strong track record

 

The Company's Board and Medicinal Cannabis Advisory Board have a combined 60 years' industry experience with strong and extensive contacts in the industry, with significant pharmaceutical strength and experience. 

 

Geremy Thomas, founder and CEO of Sativa, who together with family members has invested £785,000, £560,000 unconditionally at 0.25p per share and, pursuant to the Subscription, a further £225,000, said:  "Our decision to list on the NEX Exchange Growth Market makes both strategic and commercial sense as the market has great access to funding, regulation that fits Sativa's needs and the fact that NEX's Growth Market is an emerging market, which matches Sativa's start-up nature and culture.  We are delighted to see such high levels of investor demand and we now look forward to working with our shareholders and developing the Company. 

 

"The Company's Board and Medicinal Cannabis Advisory Board strongly believes that the dynamic regulatory environment of Canada's Medicinal Cannabis sector is the standard-bearer and will take off in key markets, as we are already seeing in the Americas and Europe, along with the strong groundswell of public support."

 

Directors Shareholdings

 

On Admission the interests of the Directors and their immediate families and, so far as they are aware having made due and careful enquiries, of persons connected with them (all of which are beneficial, unless otherwise stated) (so far as is known to the Directors, or could with reasonable diligence be ascertained by them) (within the meaning of sections 252 to 254 of the UK Companies Act 2006) in the Issued Share Capital are and will be as follows:

 

Director	Number of Ordinary Shares on Admission	% of Issued Share Capital
Geremy Thomas	224,000,000	52.97
Mark Blower	6,000,000	1.42
Noel Lyons	3,000,000	0.71

 

Notifiable Interests

 

In addition to the Directors holdings disclosed above, the Company has been notified or is aware of the following holdings which will, following Admission, represent more than 3 per cent. of the Issued Share Capital or voting rights of the Company:

 

Name	Number of Ordinary Shares on Admission	% of Issued Share Capital
Andrew McDonald	18,000,000	4.26
Clive Lonsdale	18,000,000	4.26
James Curtis	18,000,000	4.26
Acqam International	18,000,000	4.26
George Thomas	18,000,000	4.26
BMAK Investments Ltd*	18,000,000	4.26

*BMAK Investments Ltd participated in the Subscription, prior to publication of the Admission Document, through an investment of £100,000 at the Subscription Price, reference to which was inadvertently omitted from the Admission Document. 
 

The Company has thus raised £1,100,000 before expenses though the issue of 198,900,000 Ordinary Shares. The Company has net funds of approximately £1,548,040 after all expenses pertaining to admission to the NEX Exchange Growth Market.

 

Broker Option

 

The Directors have agreed to make available their allocated options for sale through Peterhouse should there be sufficient demand in the market following Admission and may also approve the issue of options to Peterhouse, at the discretion of the Directors, subject to demand and agreement with Peterhouse.

Total Voting Rights

Following the issue of the 198,900,000 Subscription Shares, the Company has 422,900,000 Ordinary Shares of 0.25p in issue, which also represents the total number of voting rights in the Company. This figure should be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure and Transparency Rules.

The definitions used in this announcement have the same meaning as they have in the Admission Document.

 

The Directors of the Company accept responsibility for the contents of this announcement.

–  Ends  –

 

For further information please contact:

 

Geremy Thomas Founder & CEO Sativa Investments PLC +44 (0) 20 7971 1255 [email protected]	Mark Blower COO & Finance Director Sativa Investments PLC +44 (0) 20 7971 1255 enqui[email protected]
NEX Exchange Corporate Adviser Guy Miller Peterhouse Corporate Finance Limited +44 (0) 20 7469 0930 [email protected]
Financial PR, IR & general media enquiries Julian Bosdet / Dylan Mark /Alejandra Campuzano    Abchurch Communications +44 (0) 20 7469 4630

 

Notes to Editors

 

Sativa will look for well-placed opportunities within the dynamic regulatory environment of the Medicinal Cannabis sector and the Company's investment strategy will focus on the production, testing and compliance, research and development, including pharmacology, commercialisation and sales and marketing of Medicinal Cannabis in jurisdictions where it is regulatorily accepted, with an initial focus on Canada.  The Company has committed to an independent legal review prior to each investment to verify compliance with the prevailing regulatory environment. 

 

The Company's equity interest in a proposed investment may range from a minority position, to a controlling interest, or to 100 per cent ownership.  The ventures that Sativa intends to acquire can either be public or private. 

The Company's Board and Medical Cannabis Advisory Board have a combined 60 years' industry experience with strong and extensive contacts in the industry, with significant pharmaceutical strength and experience.  Their extensive skills range from capital fund raisings, medical research, and start-ups, to pharmaceutical development. 

For more information on Sativa Investments, please visit: https://sativainvestments.co.uk/ 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

NEXFKFDPABKDDNB

Close

×

RNS Number : 1488J

LoopUp Group PLC

28 March 2018

 

 

 

 

 

28 March 2018

LOOPUP GROUP PLC

 

("LoopUp Group" or the "Group")

 

Expansion into Australia

 

Two new business acquisition 'Pods' being established

 

 

LoopUp Group plc (LSE AIM: LOOP), the premium remote meetings company, is pleased to announce its commercial expansion into the $275m Australian market1 with the formal opening of its Sydney office.

 

The Group has operated one of its four global datacenters in Australia since 2016 to serve its UK and US customers who have local operations in the region. That will now be augmented with a commercial office presence, where new business acquisition 'Pods' will target enterprises headquartered in Australia.

 

Steve Flavell, co-CEO of LoopUp, commented, "Australia has some very attractive attributes as a new market for LoopUp. There are several geographically-dispersed urban centres which drive conferencing activity, average selling prices are materially higher than the global average, and Sydney represents a wonderful focal point to develop into the Group's regional headquarters over time."

 

During a market research and testing phase over recent months, the Group has already contracted six customer wins, including a leading Australian private equity firm and a financial advisory and investment management group with over $100bn under management.

 

The Group has relocated five established members of its UK and US Pods to Sydney. Those employees will form the basis of two initial Australian Pods, which will be augmented with local graduate hires. During the first half of the current financial year, the two Pods will focus on building their pipelines to normalised Pod levels. The Group believes the Australian market is highly conducive to the LoopUp product proposition and expects growth and Pod performance to fall in line with normal UK and US pod levels thereafter.

 

1. Source: Wainhouse Research '2017 Asia Pacific Audio Conferencing Services Market Sizing' and '2017 Asia Pacific Personal Web-based Conferencing Services Market Sizing'

 

For further information, please contact:

 

LoopUp Group PLC	via FTI
Steve Flavell, co-CEO
Panmure Gordon (UK) Limited	+44 (0) 207 886 2500
Dominic Morley / Alina Vaskina (Corporate Finance)
Erik Anderson / Amy Sarra (Corporate Broking)
Numis Securities Limited	+44 (0) 207 260 1000
Simon Willis/Jonny Abbott (Corporate Finance)
Tom Ballard (Corporate Broking)
FTI Consulting, LLP	+44 (0) 203 727 1000
Matt Dixon / Harry Staight

 

 

About LoopUp Group plc

 

LoopUp (LSE AIM: LOOP) is a premium remote meetings solution. Streamlined and intuitive, LoopUp is built for business users and delivers the quality, security and reliability required in the enterprise. One-click screen sharing and integration with tools business people use every day, like Outlook™, make it easy for LoopUp users to collaborate in real time. LoopUp's award-winning SaaS solution doesn't overwhelm users with features, and doesn't require training. Over 2,000 enterprises worldwide, including Travelex, Kia Motors America, Planet Hollywood, National Geographic, and Subaru trust LoopUp with their remote meetings.

 

The Group is headquartered in London, with offices in San Francisco, New York, Boston, Hong Kong, Barbados and Australia, and is listed on the AIM market of the London Stock Exchange (LOOP). For further information, please visit: www.loopup.com.

Notes:

 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014.

 

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

MSCJRMFTMBJTBBP

Close

×

Neville Registrars is delighted to welcome Consolidated Growth Holdings Limited as the newest addition to its list of client companies.

Information on Consolidated Growth Holdings can be found on the Company website: http://www.cgh-limited.com/

Close

×

RNS Number : 5698I

EU Supply PLC

22 March 2018

 

22 March 2018

EU Supply plc

("EU Supply", the "Company" or the "Group")

 

Contract Win Denmark

 

EU Supply (LSE AIM: EUSP), the e-procurement software provider, is pleased to announce that the Group has been awarded a contract by the Danish Competition and Consumer Authority ("Authority") for delivery of CTMTM as SaaS and related services to the Authority. There is also an option for up to 6 other authorities in Denmark within the Ministry of Industry, Business and Financial Affairs to join the contract.

 

 

FURTHER ENQUIRIES

EU Supply PLC Tel: 020 7127 4545 Thomas Beergrehn, CEO   Fredrik Wallmark, CFO       Stockdale Securities Tel: 020 7601 6100 Tom Griffiths, Ed Thomas

 

A copy of this announcement is available at www.eu-supply.com.

 

Notes to Editors

EU Supply is the UK holding company of the EU Supply Group, a Sweden-based e-commerce business, which has an established, market-leading, multilingual e-procurement platform for esourcing, e-tendering and contract management, tailored for the highly regulated European public sector market.

Since 2006, the Group has invested heavily in employing specialist programmers to add functionality, legal compliance as required and security features to its Complete Tender Management™ ("CTM™") platform to ensure that the Group is ideally placed to secure new contracts with EU Member States and their Contracting Authorities. The platform is available in 16 different languages.

The Directors believe that the Group's CTM™ platform is one of the easiest to use and most functionally advanced solutions available in the market. The CTM™ platform is used by over 8,000 European public sector bodies in 9 EU/EEC Member States and has National Procurement System status in four Member States (the UK, Ireland, Norway and Lithuania).

The Company's shares were admitted to trading on AIM in November 2013. In August and September 2015, the Company raised a total of £2.061m (before expenses) through a placing of new shares and the issue of first and second tranches of Convertible Loan Notes to institutional and other investors.

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

NRASEUSAEFASEED

Close

×

Neville Registrars is delighted to welcome Bellzone Mining plc as the newest addition to its list of client companies.

Bellzone Mining is an emerging iron ore and nickel exploration and development Company operating in the Republic of Guinea, West Africa.

Further information can be found on the Company's website: http://www.bellzone.com/

Close

×

Neville Registrars is delighted to welcome First Sentinel Plc as the newest addition to its list of client companies.

First Sentinel is an alternative investment company, registered with the FCA as a small authorised UK AIFM, which provides growth capital for public and private company investments. First Sentinel PLC invests in a range of debt and equity instruments in target portfolio companies.

Further information can be found on the Company's website: https://first-sentinel.com/

Close

×

RNS Number : 0433H

Concepta PLC

08 March 2018

 

8 March 2018

Concepta plc

("Concepta" or the "Company")

 

myLotus obtains Ethics Committee approval to commence trial in UK

Concepta plc (AIM: CPT) the UK healthcare company and developer of a proprietary product targeted at the mobile health market with a primary focus on women's fertility, is pleased to announce that it has received Ethics Committee* approval to commence the user trial for its myLotus product in the UK.

Concepta has engaged the renowned UK-based company, The Clinical Trial Company, which specialises in clinical studies for pharmaceutical, biotechnology and medical device companies to manage the trial, which will be conducted in Rhyl, UK.

The trial is expected to commence in the next month, with 120 women testing the device for ease of use and clarity of instructions. Patient recruitment for the trial, the process of testing, collecting samples, reporting, result analysis and the final report is expected to take approximately four months. The results will be included alongside those of the stability trials1 and the technical file2 to support the Company's CE-mark.

Concepta also announces that the myLotus product format and the labelling for EU markets has been finalised and it is currently waiting to undergo the strict audit process of the Company's Notified Body: BSI. The audit is expected to be carried out upon completion of the trial in order to obtain final CE-marking.

Erik Henau, CEO of Concepta commented: "We are delighted to announce this important milestone. Over the last few months, we have dedicated considerable effort to meet the necessary requirements and regulations in order to expedite our CE-marking process. We look forward to obtaining this key certification in the coming months, which will allow us to launch our myLotus product in our initial target European markets of the UK, and subsequently, other EU markets as the Company grows."

 

Enquiries:

The Company

Erik Henau

CEO

Tel: +44 (0) 1234 866601

 

SPARK Advisory Partners Limited (Nomad)

Neil Baldwin / Mark Brady

Tel: +44 (0)20 368 3550

 

NOVUM Securities Limited (Broker)

Colin Rowbury

+44 (0) 20 7399 9400

 

Yellow Jersey (Financial PR)

Georgia Colkin / Joe Burgess / Katie Bairsto

Tel: +44 (0) 776 932 5254

 

 

Notes to Editors

Concepta Plc

Concepta plc is an AIM-quoted pioneering UK healthcare company that has developed a proprietary product, myLotus, targeted at the personalised mobile health market with a primary focus on unexplained infertility† in women.

myLotus is currently the only consumer product which allows both quantitative and qualitative measurements of a woman's personal LH and human chorionic gonadotropin (hCG) hormone levels in a home test, facilitating higher conception rates and early diagnosis of issues with fertility hormones. The proposition of myLotus is to help women conceive naturally.

Concepta has made significant progress recently, establishing agreements with a number of distributors in China where myLotus has been given cFDA approval. Concepta is initially targeting the traditional route to market in China through Chinese hospitals and plans to add the direct-to-consumer route in the near future. 

The Company is also well on its way to achieving CE-marking and commencing its direct-to-consumer launch in the UK and Europe in H1 2018. The Company has identified a significant global market opportunity, with revenue potential of the Chinese and EU unexplained infertility market estimated to be worth c.£600m per annum.

†Unexplained infertility refers to women that have been unable to conceive after 6 months of trying. This highly motivated target group of consumers won't typically be offered medical intervention until 12 months of unsuccessfully trying, with IVF not offered until two years. Research indicates couples start to take positive action ahead of this time and there is little medical support to help them do so.

 

*Ethics Committees

There are more than 80 NHS Research Ethics Committees across the UK. They exist to safeguard the rights, safety, dignity and well-being of research participants.

RECs consist of up to 15 members, a third of whom are 'lay' – their main professional interest is not in a research area, nor are they a registered healthcare professional.

RECs review research proposals and give an opinion about whether the research is ethical. They also look at issues such as the participant's involvement in the research. The committees are entirely independent of research sponsors (the organisations responsible for the management and conduct of the research), funders and the researchers themselves. This enables them to put participants at the centre of their review.

 

About RNS Reach announcements

RNS Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases such as marketing messages, corporate and product information into the public domain. An RNS Regulatory announcement is required to be notified under the AIM Rules for Companies.

 

---

1 Stability trials provide evidence on how the quality of the medical device varies with time under the influence of environmental factors, such as temperature, and are necessary for establishing a shelf life for the device and for recommended storage conditions.

 

2 A technical file is a set of documents that describes a product and can prove that the product was designed according to the requirements of a quality management system. Concepta operates under ISO13485 as its Quality Management System.

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

NRAJRMRTMBAMBAP

Close

×

RNS Number : 4689G

React Group PLC

02 March 2018

 

2 March 2018 

                                                                                React Group plc

                                               (the ''Company'' or ''React'')

                          Additional Contract win with Major London Hospital

 

REACT Group plc (AIM: REAT), the specialist provider of rapid response deep cleaning and emergency decontamination services, is pleased to announce that its subsidiary, REACT Specialist Cleaning Limited (''RSCL''), has signed an additional Service Contract with a major facilities company for the provision of deep cleaning services for the same major London hospital as the initial contract announced on 11 September 2017.

 

The Service Contract is for a period of 18 months.  It covers both deep cleaning and that RSCL has been appointed as preferred supplier for other ad hoc work.

 

RSCL has been awarded initial purchase orders totalling £206,000 (excluding VAT), for deep cleaning work under the Service Contract.  The additional provision under the Service Contract for other ad hoc services is significant.  This is because whilst there is no guarantee as to the level of additional work, REACT is now the preferred supplier and similar ad hoc services from this client contributed in excess of £250,000 to revenue in the previous financial year ended 30 September 2017.

 

Gill Leates, the Chairman said, 'We are very pleased that the company has continued to build more contract work, which reflects on the high standards that our teams continue to deliver.  We will continue our strategy of developing the business in our areas of core expertise'.

 

For further information please contact:  

 

REACT Group plc
Gill Leates – Chairman	07799 662642
SPARK Advisory Partners Limited
Neil Baldwin	0113 370 8974
Mark Brady	0113 379 8971
Whitman Howard Limited
Nick Lovering	0207 659 1224

    

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

CNTLLFSTVLILIIT

Close